Gyros AB announces license and development agreement with Fujirebio Inc, Japan
Gyros AB has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros' proprietary Compact Disc technology.
Under the terms of the agreement, Fujirebio will investigate combining Gyros' Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications. Jan Würtz, CEO & President of Gyros AB said; "Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics technology for clinical diagnostic applications. Miniaturization and integration of immunoassays using Gyros' Compact Disk format could give significant productivity gains compared to traditional ways of working."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.